| Erbitux May Not Help Colon-Cancer Survival for Some Colon-cancer drug Erbitux didn't extend survival in a certain group of patients when added to chemotherapy, a study finding researchers called surprising. online.wsj.com |
Roche's Diabetes Dreams Fade as Taspo Data Deteriorates EP Vantage submits:As anticipated, Roche’s (RHHBY.PK) huge phase III taspoglutide clinical programme was a dominant feature at this year’s American Diabetes Association (ADA) conference. What was wholly unexpected, as recently as two weeks ago, was that the data would prompt speculation that the end is nigh for the product. The fall from grace for taspoglutide, a drug earmarked as the fourth GLP-1 agonist to reach the market but forecast to be one of the most successful commercially, has been remarkably swift (see table below). A presentation to the financial community Monday night, when Roche confirmed that the hypersensitivity reactions were anaphylactic in nature, appears to have convinced many analysts that the chances of the drug reaching the market have fallen dramatically. Doctors at the ADA were more cautious in their conclusions, but it is hard to believe that taspoglutide is going to play as significant a role in the future GLP-1 market as previously thought.Complete Story » seekingalpha.com |
Judge Roils Stem-Cell Research A U.S. judge blocked the federal government from funding research involving human embryonic stem cells, a surprise blow to one of the most promising yet controversial areas of scientific research. online.wsj.com |
Swapping Out a Deadly Gene In a boost to the resurgent field of gene therapy, a technique that fixed a defective gene has allowed a patient with a blood disorder to avoid blood transfusions for more than two years. online.wsj.com |
Long Term Care Family Concerns - Video What Alarms Americans Most About Having a Long Term Care Illness? feedproxy.google.com |